BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Witjes CD, ten Kate FJ, Verhoef C, de Man RA, IJzermans JN. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers. J Clin Pathol. 2013;66:687-691. [PMID: 23585667 DOI: 10.1136/jclinpath-2012-201156] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Korenbaum C, Barthelemy P, Onea A, Salze P, Kurtz JE. "Hockey Stick" may Strike Back: Hepatocellular Carcinoma on Noncirrhotic Liver as a Late Toxicity of Lombo-Aortic Radiotherapy for Seminoma. A Review Triggered by an Unusual Case. J Clin Exp Hepatol 2016;6:54-8. [PMID: 27194897 DOI: 10.1016/j.jceh.2015.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ceausu M, Socea B, Serban D, Smarandache CG, Predescu D, Bacalbaşa N, Slavu I, Tulin A, Alecu L, Ceauşu Z. Heterogeneity of antigenic constellation in human hepatocellular carcinoma. Exp Ther Med 2021;21:270. [PMID: 33603877 DOI: 10.3892/etm.2021.9701] [Reference Citation Analysis]
3 Liu Y, Li H, Ye N, Luo CJ, Hu YY, Wu H, Gong JP. Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Med Sci Monit 2019;25:6615-23. [PMID: 31479436 DOI: 10.12659/MSM.915722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Zhao CL, Hui Y, Wang LJ, Yang D, Yakirevich E, Mangray S, Huang CK, Lu S. Alanine-glyoxylate aminotransferase 1 (AGXT1) is a novel marker for hepatocellular carcinomas. Hum Pathol 2018;80:76-81. [PMID: 29883780 DOI: 10.1016/j.humpath.2018.05.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Menz A, Bauer R, Kluth M, Marie von Bargen C, Gorbokon N, Viehweger F, Lennartz M, Völkl C, Fraune C, Uhlig R, Hube-Magg C, De Wispelaere N, Minner S, Sauter G, Kind S, Simon R, Burandt E, Clauditz T, Lebok P, Jacobsen F, Steurer S, Wilczak W, Krech T, Marx AH, Bernreuther C. Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. Hum Pathol 2021;115:19-36. [PMID: 34102222 DOI: 10.1016/j.humpath.2021.05.012] [Reference Citation Analysis]
6 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 Chen J, Liu J, Jin R, Shen J, Liang Y, Ma R, Lin H, Liang X, Yu H, Cai X. Cytoplasmic and/or nuclear expression of β-catenin correlate with poor prognosis and unfavorable clinicopathological factors in hepatocellular carcinoma: a meta-analysis. PLoS One. 2014;9:e111885. [PMID: 25401330 DOI: 10.1371/journal.pone.0111885] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
8 Zaghloul RA, El-Shishtawy MM, El Galil KH, Ebrahim MA, Metwaly AA, Al-Gayyar MM. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. Eur J Pharmacol 2015;746:353-62. [PMID: 25449037 DOI: 10.1016/j.ejphar.2014.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
9 Pho-Iam T, Punnakitikashem P, Somboonyosdech C, Sripinitchai S, Masaratana P, Sirivatanauksorn V, Sirivatanauksorn Y, Wongwan C, Nguyen KT, Srisawat C. PLGA nanoparticles containing α-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line. Biochem Biophys Res Commun 2021;553:191-7. [PMID: 33774221 DOI: 10.1016/j.bbrc.2021.03.086] [Reference Citation Analysis]
10 Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014;588:377-382. [PMID: 24140348 DOI: 10.1016/j.febslet.2013.10.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
11 Gong ZJ, Cheng JW, Gao PT, Huang A, Sun YF, Zhou KQ, Hu B, Qiu SJ, Zhou J, Fan J, Yang XR. Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. Oncologist. 2019;24:997-1007. [PMID: 30910867 DOI: 10.1634/theoncologist.2018-0268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Tai BJ, Yao M, Wang L, Qian Q, Shi Y, Yu DD, Lu SL, Yao DF. Down-regulation of glypican-3 gene transcription inhibits hepatoma cell invasion and angiogenesis. Shijie Huaren Xiaohua Zazhi 2014; 22(16): 2221-2228 [DOI: 10.11569/wcjd.v22.i16.2221] [Reference Citation Analysis]